Introduction
The medical community has long recognized that children are not small adults, particularly in terms of medication effectiveness and safety, 1 and that psychotropics and other medications with central nervous system effects can be harmful to the developing brain. 2 Nevertheless, the practice of treating young children with psychotropics lacking Food and Drug Administration (FDA) approval ("off-label" prescribing) remains common. [3] [4] [5] [6] [7] A case in point is the use of antipsychotics, namely second-generation antipsychotics, in prepubertal children. As of the fall 2015, risperidone and aripiprazole are the only secondgeneration antipsychotics that have FDA-approved indications for children 0-9, and only for the treatment of irritability associated with autism, a diagnosis that a relatively small proportion of child antipsychotic users have received. 5 However, second-generation antipsychotics have been used increasingly by young children for multiple other conditions including attention deficit hyperactivity disorder (ADHD), conduct disorder, psychosis, and mood disorders, [3] [4] [5] [6] [7] despite caution urged by the American Psychiatric Association (in its Choosing Wisely Recommendations), and the Academy of Child and Adolescent Psychiatry (AACAP). 8, 9 Their use in preschoolers (0-4 years old) has been received with particular alarm. 2, 10, 11 While the risks of antipsychotic use in adult populations are well established, [12] [13] [14] [15] the risks in children are still the subject of active research. 16, 17 However, there is growing evidence that antipsychotics, including frequently-used second-generation antipsychotics, are associated with serious cardiometabolic side effects, such as excessive weight gain, hypertension, and lipid and glucose abnormalities, when used in children. 18, 19 The importance of this association is amplified by evidence that cardiometabolic disturbances in childhood predict adult cardiometabolic outcomes. 20 Not only is there evidence that children are more vulnerable to these risks than adults, 21, 22 but there is also evidence that the youngest of the young are at even higher risk. 19, 23 Studies have found that off-label child antipsychotic use is associated with illness severity (psychiatric comorbidity, history of psychiatric hospitalizations) and severely disruptive behaviors, [24] [25] [26] [27] which suggests that child prescribers may use antipsychotics when psychosocial treatments are not accessible or effective or may prescribe off-label when FDA-approved treatment options have been exhausted. 28 Hence, although potentially justifiable, the common and growing practice of off-label antipsychotic prescribing to young children warrants scrutiny given the absence of evidence of efficacy, 29 evidence of significant cardiometabolic risks, serious concerns about harmful effects on the developing brain, and the availability (if uneven accessibility) of safer alternative treatments. Also of concern is the documented association between antipsychotic use in young children and geographic region, race, and indicators of social disadvantage such as Medicaid and foster care. 25, 30, 31 While previous studies have identified child characteristics associated with antipsychotic use, 3-4,5,6,7, 10, 16, 27, 31-32, 33, 34, 35 our focus is on describing characteristics of physicians who prescribe antipsychotics to young children and examining their prescribing patterns using a unique physician-level, all-payer prescription database. Although evidence suggests that the limited armamentarium of efficacious therapies for children with disruptive behaviors and limited accessibility to evidence-based psychosocial interventions may drive some of the off-label antipsychotic prescribing, [36] [37] [38] little is known about prescriber factors that influence use in young children or how the types and concentration of prescribing may differ for young children versus adults.
Methods
We obtained monthly physician-level prescribing information from IMS Health's Xponent™ database, which directly captures over 70% of all US prescriptions filled in retail pharmacies and utilizes a patented projection methodology to represent 100% of prescriptions filled in these outlets. IMS Health provided Xponent™ data on all U.S. physicians classified as psychiatrists in the American Medical Association Masterfile (n = 29,857) and a 5% random sample of physicians classified as family medicine physicians (n = 1,856) who wrote at least ten antipsychotic prescriptions per year from 2008-2011. The Xponent™ data includes information on the payer (Medicaid fee-for-service (FFS), Medicare, commercial, or cash) and the age category of the patient (using IMS-provided categories 0-9, 10-19, 20-64, 65+). For the purposes of this study, we define young children as those 0-9. Because the data are obtained from pharmacy transactions and not medical claims they lack patient clinical information (e.g., diagnosis codes). We linked the Masterfile data on physician characteristics (age, sex, geographic location, training institution, and practice setting) to the Xponent™ prescribing data using a prescriber ID. As a result, these data include detailed information on physician characteristics and comprehensive physician-level data on prescribing patterns across all payers for over 31,000 psychiatrists and family medicine physicians who prescribe antipsychotics.
To identify physician characteristics associated with prescribing antipsychotics to young children, we estimated a logistic regression model of whether a physician had any child 0-9 antipsychotic prescriptions over the period 2009-2011 (using 2008 Next, we compared prescribing patterns for young children versus adults 20-64 among the subset of physicians who had at least one prescription for both age groups (n=13,214). We were interested in whether prescribers chose from a different, and possibly narrower, set of antipsychotics given the limited number of products with FDA approval for use in young children. We first compared the share of all antipsychotic prescriptions written for each medication for the patients in the two age groups. We then examined the distribution of the number of different antipsychotic medication ingredients prescribed by physicians for patients in the two groups, both overall, by specialty, and by quartile of 2008 total antipsychotic prescribing volume. Because of the very low use of first-generation antipsychotics (see Appendix for list) among young children, all first-generation antipsychotics were treated as a single ingredient.
We also identified factors associated with prescribing of antipsychotics for which there are no FDA-approved indications for young children. As noted above, only two secondgeneration antipsychotics, risperidone and aripiprazole, had an approved indication for children 0-9 (see Appendix). Four first-generation drugs -chlorpromazine, haloperidol, prochlorperazine, and trifluoperazine -had approved indications for children 0-9, and prescriptions for these were categorized accordingly, although these drugs were rarely used in young children.
We estimated a hierarchical binomial regression model of the physician's number of young child prescriptions for antipsychotics with no approved indications for children 0-9. We assumed the number of child 0-9 prescriptions for antipsychotics with no approved indications for each physician arises from a binomial distribution characterized by a physician-specific probability, p. We modeled the log-odds of the probability of these prescriptions as a function of the same variables as the logistic regression model described above with two additions --specialty (child/adolescent psychiatry, other psychiatry, family medicine) plus a physician-specific random effect. The random effect was assumed to be normally distributed with mean 0 and unknown variance τ 2 ; the random effect accounted for clustering of prescriptions written by each physician as well as different physician volumes. We computed odds ratios and corresponding 95% confidence intervals for the physician characteristics. To characterize the degree of between-physician variation in the probability of writing these prescriptions, after adjusting for physician characteristics, we determined the odds a child 0-9 years received such a prescription from a "high" prescriber relative to a "low" prescriber. A high prescriber was operationalized as one who was one standard deviation, τ, above the mean of the physician random effects. To determine whether physicians writing few prescriptions impact our findings, we repeated the binomial regression analysis restricting to physicians with at least 30 prescriptions. This study was approved by the XXX Institutional Review Board. All analyses used SAS version 9.4.
Results
Of the 31,713 physicians, 13,374 (42.2%) wrote at least one antipsychotic prescription to a patient 0-9 during the three-year period. Physicians with any prescriptions for young children differed along a number of dimensions from prescribers with no prescriptions for this population (Table 1) .
Factors Associated with Any Child 0-9 Prescribing
On average, younger physicians were more likely to prescribe antipsychotics to young children (odds ratio [95% confidence interval] for ≤39 years, 40-49, and 50-59 relative to 60+ are: OR=1.70; CI=1.54-1.89, OR=1.40; CI=1.30-1.50, and OR=1.22; 1.14-1.29), and male physicians were less likely to do so than female physicians (OR=.93; CI=.88-.98) ( Table 2) . Physicians in rural areas were more likely to prescribe to children 0-9 (OR=1.11; CI=1.02-1.21), and those practicing in other types of settings besides group practices were less likely relative to physicians practicing in one-or two-person practices (OR=.86; CI=. 80-.92). Graduates of top 25 medical schools were less likely to prescribe to children 0-9 (OR=.87; CI=.81-.94). The likelihood of prescribing to young children increased with total antipsychotic prescribing volume and the share of the physician's prescriptions paid for by Medicaid FFS (OR=9.25; CI=8.28-10.34), decreased with the share paid by cash (OR=.54; CI=.34-.86), and varied by geographic region.
Comparison of Prescribing to Children 0-9 vs. Adults 20-64
Use of specific medications varied among physicians who prescribed both to young children and adults. Three-quarters of young child prescriptions were for risperidone (50.6%) and aripiprazole (24.4%) (Figure1). In contrast, only 35.7% of their adult prescriptions were for these drugs (risperidone 19.5% and aripiprazole 16.1%). Quetiapine was the most commonly prescribed drug for adults (24.0% of prescriptions). Notably, although more firstgeneration antipsychotics have FDA approval for this age group and little evidence exists of their cardiometabolic risks, physicians used them rarely for young children (1.7% of prescriptions), and much less often than for adults (16.1%).
Among these physicians with prescriptions both to young children and adults, the median number of different ingredients used across their young child patients was 2 (Interquartile Range (IR)=1,4). Physicians used a much broader set of ingredients for their adult patients, with a median of 7 (IR=6,8) different ingredients ( Table 3 ). The median number of ingredients for young child prescriptions was higher for child/adolescent psychiatrists (3) than for family medicine physicians (1) and other psychiatrists (2) . The median number of ingredients also increased with total antipsychotic prescribing volume (median=2 for the first and second volume quartiles and 3 for the third and fourth volume quartiles).
Factors Associated with Number of Child 0-9 Prescriptions for Antipsychotics with No FDA-Approved Indications for that Age Range
Among the 13,374 physicians with at least one antipsychotic prescription for a young child, almost two-thirds (64.0%) had at least one prescription for a medication with no FDAapproved indications for that age range.
On average, physicians age 40-49 and 50-59 were more likely to prescribe antipsychotics with no FDA-approved indication for young children than older physicians (OR=1.18; CI=1.05-1.30 and OR=1.13; CI=1.02-1.24, respectively) ( Despite adjusting for these characteristics, substantial between-physician variation in prescribing of medications with no approved indication for young children remained. The between-physician variance component, after adjusting for physician characteristics, was 3.65 (s.e.=0.0747). This roughly translates to a range in odds ratio of 45 across all prescribers, implying that the odds of a prescription with no approved indications for children 0-9 for a moderately "high" prescriber of medications with no approved indications is 45 times that when treated by a moderately "low" prescriber. When restricting to physicians writing at least 30 antipsychotic prescriptions (n=7065, 53% of all physicians), our substantive findings generally did not change, although the child/adolescent psychiatrist, prescription share paid by Medicaid, and rural effects were no longer statistically significant. The between-physician odds ratio decreased to 21, still indicating substantial betweenphysician variation.
Discussion
Using all-payer, physician-level prescription data on psychiatrists and family medicine physicians who prescribed antipsychotic medications over the period 2009-2011, we found that almost half of prescribers had written at least one antipsychotic prescription for a child 0-9. Prescribing to young children was more common among younger physicians, those practicing in rural areas, those with higher total antipsychotic prescribing volume, and those with a higher share of prescriptions paid by Medicaid FFS programs. It was less common among physicians practicing outside of groups, two-person or solo practices; physicians who graduated from a top 25 medical school; and physicians with a high share of antipsychotic prescriptions paid by cash. While three-quarters of prescriptions for young children were for the two drugs with an FDA-approved indication for children in that age range, almost twothirds of physicians who prescribed to young children had at least one prescription for a medication with no FDA-approved indications for children 0-9. This is in spite of the fact that physicians tended to prescribe from a narrow set of antipsychotics (typically two) for young children.
While previous studies using patient-level claims and survey data have documented rates of antipsychotic use in young children, [3] [4] [5] [6] [7] little is known about the characteristics of physicians who prescribe these medications to young children or about the patterns of prescribing in this age group. Our results show that physicians treating both adults and children appear to tailor their prescribing to some extent based on age group, adopting what may be a more conservative approach for young children. Physicians are more likely to prescribe an antipsychotic with an FDA-approved indication for this age group to their young child patients (even if the medication may be prescribed for a different condition than the approved indication), and they use a much smaller number of ingredients for those patients relative to their adult patients.
A number of strategies, including prior authorization and step therapy requirements, [39] [40] [41] [42] [43] [44] tiered formularies, 45, 46 monitoring and feedback (e.g., computerized alerts, reminders, audit and feedback), 47 academic detailing, 48, 49 and policies restricting detailing efforts by pharmaceutical manufacturers 50 have proven effective at influencing physician prescribing behavior in general. Payers and health plans could consider applying these approaches to antipsychotic prescribing to young children in an effort to highlight for prescribers the riskbenefit tradeoffs associated with antipsychotic use in children. That some antipsychotic prescribing among young children may be occurring as a result of limited access to nonpharmacologic evidence-based treatments, particularly when the behaviors are disruptive as is often the case with severely hyperactive children with ADHD, 26, 36 points to the need for broader interventions focused on the competencies and geographic distribution of the mental health workforce and financing of mental health services. 37, 38, 51, 52 It is significant in this regard that federal and state agencies have already launched initiatives aimed at improving the appropriateness of child psychotropic prescribing, especially for children in foster care. 30, 53 New HEDIS measures focused on the safe prescribing of antipsychotics for children have also drawn increased attention to this issue from payers, health plans, and provider organizations.
There are several limitations to our analysis. First, our dataset lacks information on the specific indication for which the physician prescribed an antipsychotic as well as information on dosing, duration of medication therapy, and whether other therapies had been tried before an antipsychotic was prescribed. Previous studies of antipsychotic use among young children have relied on claims data (often from a single state Medicaid program or private insurer) 3, 4, 6, 7, 31 or the National Ambulatory Medical Care Survey (NAMCS), which asks a sample of physicians about patient visits over a one-week period. 5, 32, 33 While claims data provide information on diagnoses and service use, some claims datasets do not include physician identification numbers or information on physician characteristics. In addition, claims data from an insurer or Medicaid program would not be representative of the universe of a physician's patients, as most physicians treat patients with a variety of payers. While NAMCS provides detailed information on a subset of visits, it is not possible to follow physicians or patients over time. The data used for this study allow us to fully characterize a physician's prescribing to young children over time and to identify physician characteristics associated with different prescribing patterns. Second, the Xponent™ data provide two age categories for children -0-9 and 10-19 --so we were obliged to define young children as those 0-9. Third, we were unable to determine whether a given prescription was for an on-vs. off-label indication due to the lack of clinical information. However, we were able to determine whether a physician prescribed to a child 0-9 a medication with no FDA-approved indications for young children. Fourth, while our dataset includes data on all U.S. psychiatrists and a random sample of family medicine physicians who prescribe antipsychotics, we do not have data on pediatricians. However, psychiatrists and family medicine physicians together accounted for three quarters (73.6%) of all child antipsychotic prescriptions filled in 2009, and pediatricians accounted for just 9.5%. 54 
Conclusions
We found that a large proportion of psychiatrists and family medicine physicians who prescribe antipsychotics write prescriptions to young children, although antipsychotic prescribing patterns appear quite different for this age group relative to adults. Given the dearth of evidence of antipsychotic efficacy in children and the growing evidence of risks associated with child antipsychotic use, payers and provider organizations could consider interventions that are targeted at physicians who prescribe antipsychotics to young children and highlight the clinical tradeoffs associated with the use of these medications in order to ensure the quality, safety, and value of child mental health treatment.
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